Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma

Conditions: Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: No

Phase: NA

Enrollment: 10

Sponsor: Qianfoshan Hospital

Location: Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China Jinan Shandong

Summary

An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis

Eligibility Criteria

Inclusion Criteria: * Female and Male patients aged 18-75 years * Diagnosis of Allergic Bronchopulmonary Aspergillosis (according to the ISHAM Working Group Diagnostic Criteria) * Severe asthma requiring treatment with high dose ICS plus a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control) Exclusion Criteria: * History of allergy or hypersensitivity reaction to Depemokimab or any of its components. * Currently pregnant, breastfeeding, or lactating women. * Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07828327). StuddyBuddy aggregates publicly available trial information.